Home Immunology & Inflammation Complement System inhibitor Compstatin

research use only

Compstatin Complement System inhibitor

Cat.No.S8522

Compstatin binds to complement component C3 and inhibits complement activation with IC50 of 12 μM.
Compstatin Complement System inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 1550.77

Jump to Mechanism of Action Cell Culture & Working Concentration Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: S852201 Water]100 mg/mL]false]]]false]]]false Purity: 99.85%
99.85

Cell Culture, Treatment & Working Concentration

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
RPE cells Function assay 50 uM Inhibition of complement activation in human fetal RPE cells assessed as reduction in C5b-9 formation at 50 uM by fluorescence assay in presence of complement-competant human serum 25494040
fetal RPE cells Function assay 15 mins Inhibition of complement activation in human fetal RPE cells assessed as hemolysis of serum-treated rabbit erythrocytes compound preincubated with serum for 15 mins measured 20 mins after erythrocyte addition by hemolytic assay 25494040
Click to View More Cell Line Experimental Data

Chemical Information, Storage & Stability

Molecular Weight 1550.77 Formula

C66H99N23O17S2

 Storage (From the date of receipt)
CAS No. 206645-99-0 Download SDF Storage of Stock Solutions

Synonyms N/A Smiles CCC(C)C(C(=O)NC1CSSCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)C(C)C)C(C)C)CCC(=O)N)CC(=O)O)CC2=CNC3=CC=CC=C32)CC4=CN=CN4)CC5=CN=CN5)CCCN=C(N)N)C(=O)NC(C(C)O)C(=O)N)N

Solubility

In vitro
Batch:

Water : 100 mg/mL

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
complement component C3 [4]
12 μM
In vitro

Compstatin binds to native C3 and inhibits its cleavage by C3 convertase. Binding of this compound to native C3 is a multistep reaction that is preferred over its binding to the C3 fragments C3b and C3c. N-acetylation of this compound provides stability against enzymatic degradation[1].

This compound features a high selectivity for human and primate C3. While binding to C3 from baboons and other primates shows comparable interaction profiles as its human counterpart, no binding is detected for C3 from lower mammalian species such as mice, rats, guinea pigs, rabbits, or pigs[3].
In vivo

Compstatin completely inhibits in vivo heparin-induced complement activation without adverse effects on heart rate or systemic arterial, central venous, and pulmonary arterial pressures. This compound is a safe and effective complement inhibitor that has the potential to prevent complement activation during and after clinical cardiac surgery. Furthermore, it can serve as the prototype for designing an orally administrated drug. In the extracorporeal circulation model, this peptide inhibits the generation of C3a and C5a, the formation of the membrane attack complex, and CD11b expression on neutrophils (PMNs). The peptide also inhibits binding of C3/C3 fragments, PMNs, and monocytes to the polymer surface[2].
References
  • https://pubmed.ncbi.nlm.nih.gov/17684013/
  • https://pubmed.ncbi.nlm.nih.gov/34388364/

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.